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on univariate analysis (HR 2.2, 95%CI 1.2-4.0, p¼0.007).
CONCLUSIONS Increased baseline cTnI in patients with stable angina
is associated with the presence of vulnerable plaques and future
MACE. These results suggest a potential mechanism underlying the
prognostic value of cTnI in patients with stable angina.
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BACKGROUND The role of anticoagulants during percutaneous cor-
onary intervention (PCI) in acute coronary syndrome (ACS) is
increasingly important. The CARTAGOMAX study aims to assess the
efﬁcacy and safety of bivalirudin (BIVA) versus unfractionated hepa-
rin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) during PCI in the
real world.
METHODS We performed a single-center and prospective study. All
patients with acute coronary syndrome (with and without ST segment
elevation) who underwent percutaneous coronary intervention in our
cardiac catheterization laboratory between January 2010 and
December 2014 were eligible for inclusion. All received loading dose of
aspirin and clopidogrel. Patients were successively anticoagulated
either with BIVA or with UFH plus GPI, in a 2:1 ratio. The main
objective was to compare mortality and major bleeding rates at 1, 6
and 12 months of follow-up. As secondary objectives, the presentation
of stroke, reinfarction and stent thrombosis was analyzed. All patients
signed informed consent. Study protocol was approved by our hos-
pital ethics committee. We performed univariate analysis and binary
logistic regression analysis. Survival analysis was performed using
Kaplan-Meier method using the log rank test, which is expressed
followed by relative risk (RR) with the 95% conﬁdence interval.
RESULTS A total of 1800 patients were included. 31,6% were diag-
nosed with ACS with ST segment elevation and 68,4% with ACS
without ST segment elevation. 1183 (65,7%) of patients received BIVA
and 617 (34,3%) were treated with UNH+GPI. Baseline characteristics
are shown in table 1. No signiﬁcant differences in mortality were
observed between the two groups at 30 days (p¼0,231; RR 0,8-2,2)
and at 6 months follow-up (p¼0,12; RR 0,9-2,1 ). At one year follow-
up, a non-signiﬁcant trend to lower mortality was observed in the
bivalirudin group (p¼0,052; RR1,01-2,15). The incidence of major
bleeding was higher in the arm treated with UNH+GPIat 1 month
(p¼0,001; RR 1,4-40,9), at 6 months (p¼0,009 RR 1,2-5,05) and at 12
months (p¼0,061; RR 0,9-3,3).Similar results were obtained when
the occurrence of cerebral ischemic events was analyzed. The
incidence of stroke ratio was lower in the BIVA arm at 1 month
(p¼0.015; RR 1,4-40,9), at 6 months (p¼0,003; RR 1,6-24,6) and at 1
year (p¼0,032; RR 1,03-7,8). The rates of re-infarction were similar
in both groups. A nonsigniﬁcant trend to higher stent thrombosis in
the BIVA arm was observed.Heparin + IGP Bivalirudin Total p valueAge, years 66,18  12,2 67,14  12,5 66,61  12,49 0,119
Female gender 129 (20,9) 327 (27,7) 456 (25,3) 0,002dyslipidemia 280 (45,4) 620 (53,4) 900 (50) 0,005Hypertension 339 (54,9) 754 (63,7) 1093 (60,7) 0,001Diabetes 211 (34,2) 513 (43,4) 724 (40,2) 0,001Smoking 286 (46,4) 537 (45,4) 823 (45,7) 0,698Radial access 278 (45,2) 723 (61,6) 1001 (56) 0,001LVEF 54,36  11 54,38  11 59,41  14,76 0,971
No diseased
vessels1,73  0,76 1,76  0,81 1,75  0,8 0,527No treated
vessels1,15  0,39 1,24  0,46 1,21  0,44 0,001No implanted
stents1,8  1,06 1,77  1,04 1,78  1,05 0,654GFR, ml/min/
1,73m287,9  44,57 87,7  42,52 87,8  43,17 0,925Platelets, mcL 217610  64750 221380  91120 220200  83773 0,405
Contrast, ml. 340  178,68 286  128,18 305,1  149,53 0,001CONCLUSIONS In the CARTAGOMAX study the use of bivalirudin
during PCI is presented as an effective and safe option, with a lower
rate of major bleeding and stroke, and similar mortality and stent
thrombosis over the use of UFH plus a GPI.
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BACKGROUND Prasugrel and ticagrelor are potent P2Y12 ADP recep-
tor inhibitors that have greater clinical efﬁcacy compared with clopi-
dogrel, but more non-CABG bleeding. There are no direct comparisons
of clinical outcomes between the drugs with follow-up through 1 year.
This retrospective study compared 1 year post discharge outcomes
between the 2 agents in acute coronary syndrome patients (pts)
managed with percutaneous coronary intervention (ACS-PCI) using a
claims database.
METHODS ACS-PCI pts  18 years, with no history of TIA or stroke, a
physician visit 90 days post discharge, and at least 1 outpatient
pharmacy ﬁll 30 days post discharge for prasugrel or ticagrelor, but
not both, were included. Data from the ProMetis Lx database were
propensity matched for prasugrel use with a 3 prasugrel:1 ticagrelor
ratio. Unadjusted clinical outcomes were assessed using descriptive
methods on an as treated basis. Propensity matched clinical outcomes
were compared using Cox proportional hazards models and Kaplan-
Meier analysis. Post discharge net adverse clinical events (NACE) at
1 year was evaluated for non-inferiority of outcomes between the
2 populations using a 20% margin. NACE was a composite of major
adverse cardiovascular events (MACE) or rehospitalization for
bleeding. MACE was the composite of all-cause death, coronary
revascularization, or rehospitalization for MI, unstable angina (UA),
TIA/stroke, or CHF.
RESULTS Of the 173,484 ACS-PCI pts in the database, 15,788 were
included (prasugrel 12,797; ticagrelor 2,991). Compared with ticagrelor
pts, prasugrel pts were younger, less likely to be female, have prior
MI, diabetes, or present with NSTEMI; more likely to have UA; no
signiﬁcant difference in the rate of STEMI. Prior to matching, prasu-
grel pts had lower rates of NACE and MACE (p<0.01), with no differ-
ence in bleeding (Table), compared with ticagrelor pts. After
propensity matching, there was no signiﬁcant difference in baseline
characteristics between the two groups. Non-inferiority was
demonstrated related to outcomes associated with prasugrel use
compared with outcomes associated with ticagrelor use (Table).
Rates of NACE and MACE remained signiﬁcantly lower in the
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with no signiﬁcant difference in the rate of all-cause death, MI, UA,
coronary revascularization, or TIA/stroke (Table).
CONCLUSIONS In this “real-world”, retrospective, observational
study in ACS-PCI pts, physicians preferentially used prasugrel in
younger pts with lower risk of bleeding or comorbidities compared
with ticagrelor, although clinical outcomes associated with prasugrel
were noninferior to those associated with ticagrelor.Unmatched Matched
Prasugrel
N[12,797
Ticagrelor
N[2,991 p
Prasugrel
N[6,969
Ticagrelor
N[2,323 p
P-NI
(20%
margin)
n (%) n (%) n (%) n (%)
NACE 2,254
(17.6%)
593 (19.8%) 0.005 1,176
(16.9%)
446 (19.2%) 0.01 <0.0001
MACE 2,053
(16.0%)
542 (18.1%) 0.006 1,078
(15.5%)
405 (17.4%) 0.03 <0.0001
Rehospitalization for
bleeding
393 (3.1%) 99 (3.3%) 0.50 196 (2.8%) 76 (3.3%) 0.26 0.0005
All-cause death, MI, or
stroke
429 (3.4%) 117 (3.9%) 0.13 231 (3.3%) 89 (3.8%) 0.24 <0.0001
Coronary
Revascularization
1,432 (11.2%) 347 (11.6%) 0.52 728 (10.4%) 272 (11.7%) 0.09 <0.0001
CHF 481 (3.8%) 164 (5.5%) <0.001 265 (3.8%) 114 (4.9%) 0.02 <0.0001
NACE ¼ Net adverse clinical events; MACE ¼ Major adverse cardiac events; MI ¼ Myocardial infarction;
CHF ¼ congestive heart failure; NI ¼ Non-inferiorityCATEGORIES CORONARY: Acute Coronary Syndromes
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BACKGROUND Spontaneous coronary artery dissection (SCAD) is a
rare and poorly understood cause of acute coronary syndrome (ACS)
and sudden cardiac death. It occurs predominantly in young women
who do not have risk factors for atherosclerosis, with an increased
proportion occurring in the peripartum period. The prevalence of
SCAD has been reported to range from 0.1% to 4% of ACS pre-
sentations. The purpose of this study is to evaluate the clinical char-
acteristics, management and outcomes of SCAD in a large
retrospective cohort of patients.
METHODS This study was conducted in the Northern California
Kaiser Permanente (KP) healthcare system using electronic databases
and medical charts. Coronary angiograms and, when available,
intravascular ultrasound from all potential SCAD cases were inde-
pendently reviewed by two interventional cardiologists. Healthy
controls with at least 9 months of KP enrollment prior to SCAD case
date were selected in a 3:1 ratio from the KP database, matching for
age, sex and follow up time from matched SCAD date. Major adverse
cardiovascular events (MACE) including recurrent SCAD, myocardial
infarction (MI), congestive heart failure hospitalization (CHF) and
death after the initial hospitalization were obtained during follow
up.
RESULTS 111 patients during 2003-2012 were identiﬁed as having
SCAD, 333 matching healthy controls were selected. The median
follow-up was 38 (range 7-119) months. SCAD patients had a mean age
of 48.1  11 years, 93% were female. 9 out of 103 (9%) women were
postpartum. 91% presented with acute myocardial infarction, 23% had
ST elevation on EKG. The left anterior descending artery was the most
frequently involved (72%) coronary artery. Precipitating emotional or
physical stress was reported in 12.6%. Fibromuscular dysplasia was
identiﬁed in 23% of femoral angiograms performed. 47% were suc-
cessfully treated conservatively without needing further revasculari-
zation. Among the 51% who had percutaneous coronary intervention
in-hospital, 2 required coronary artery bypass surgery for SCAD
extension. Hyperlipidemia and pregnancy were signiﬁcantly more
frequent in SCAD cases than controls. Among SCAD patients, MACE
occurred in 9% (0 deaths, 3 recurrent SCAD, 5 MI, 1 CHF) and among
the controls, MACE occurred in 1% (1 non cardiovascular related
death, 1 MI, 1 CHF). 47% SCAD patients had at least one repeatemergency room visit or hospitalization for troponin-negative chest
pain. 19 of 44 (43%) repeat angiographies were performed more than
20 days after initial SCAD, with 80% of them showing spontaneous
healing.
CONCLUSIONS SCAD affects predominantly young women, majority
presenting as acute myocardial infarction. Pregnancy and hyperlip-
idemia are more frequent in SCAD than controls. All patients treated
conservatively initially did not require revascularization. The SCAD
recurrence rate was very low and the mortality rate was zero. How-
ever there was a high rate of troponin-negative chest pain emergency
room visit or hospitalization during follow-up.
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BACKGROUND Subacute stent thrombosis (SST) (0 – 30 days) remains
an important complication post primary percutaneous intervention
(PPCI), with morbidity and mortality reaching those of spontaneous
myocardial infarction. To date, our information on angiographic and
clinical predictors of SST in ST- segment elevation myocardial
infarction (STEMI) patients treated with PPCI is limited. We tried to
analyse the clinical and angiographic predictors of SST in a large
cohort of STEMI patients treated with PPCI and coronary stent
deployment. Secondly, we wanted to assess if SST is associated with
higher 30-day mortality in the current era.
METHODS We identiﬁed all the patients presenting as STEMI be-
tween June 2004 and January 2011 who underwent PPCI with stent
deployment as the primary mode of revascularization. Diagnosis of
stent thrombosis was made as per the standard deﬁnition proposed
by the Academic Research Consortium (ARC). Patients were divided
into with and without SST. Patients in both groups were compared
for basic clinical and angiographic characteristics.
RESULTS A total of 2303 patients underwent PPCI with coronary stent
deployment. The overall rate of SST was 1% (n ¼ 24). Deﬁnite and
probable EST occurred in 22 and 2 patients respectively. All but 1
patient with SST had received bare metal stent. The baseline charac-
teristics of the patients are shown in Table 1. There was no signiﬁcant
difference between access site (transradial vs. femoral), type of
anticoagulant use (bivalirudin vs. heparin), aspiration
thrombectomy, use of GPIIbIIIa or the infarct related artery between
the two groups. Patients with SST had higher in-hospital (p ¼ 0.03)
and 30 day mortality (p ¼ 0.048). However, there was no signiﬁcant
difference in mortality at 6 months between the two groups. The
rate of cardiogenic shock (p ¼ 0.0006) and cerebrovascular accident
(p ¼ 0.0004) was higher in the SST group. On IVUS imaging of SST
cases, under deployment of stent and uncovered plaque area was
noted in nearly half of the cases.SST
(N[24)No SST
(N[2279) P ValueMen 20 (83%) 1670 (73%) 0.26Age (yrs) 59  11 61  13 0.37
Hypertension 9 (38%) 1076 (47%) 0.34Diabetes 2 (8%) 387 (17%) 0.26Hyperlipidemia 11 (46%) 884 (39%) 0.56Smoking 9 (38%) 965 (42%) 0.63Previous MI 2 (9%) 280 (12%) 0.54Previous CABG 0 73 (3%) 0.37BMI 28  5 27  4 0.21
Systolic BP (mmHg) 132  24 131  20 0.48
Hemoglobin (g/dl) 141  18 141  24 0.26
Creatinine (mmol/L) 96  53 96  34 0.96CONCLUSIONS Incidence of SST in PPCI cohort is around 1%. It is still
associated with higher mortality and cardiogenic shock. Under
